title: [Inflammatory bowel disease: should all patients be premedicated when infliximab is administered to reduce infusion reactions and/or immunogenicity?].
authors.affiliation: Servicio de Aparato Digestivo, Hospital Son Dureta, Palma de Mallorca, España. dginard@hsd.es
authors.forename: Daniel
authors.initials: D
authors.lastname: Ginard
authors.forename: Zoe
authors.initials: Z
authors.lastname: Mariño
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology*; D000917:Antibody Formation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology*; D000069285:Infliximab; D007262:Infusions, Intravenous / Q000009:adverse effects; D011292:Premedication
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab